Opioid Use DisorderPhase 1NCT05447286

Safety, Tolerability and Pharmacokinetics of NYX-783 and Oxycodone DDI Study

A Phase 1 study testing NYX-783 and Oxycodone in people with Opioid Use Disorder, run by Yale University at 2 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

This study proposes to examine the safety, tolerability, and pharmacokinetics (PK) of NYX-783 50 mg and 150 mg versus Placebo (PBO) in combination with acute Oxycodone 15 mg and 30 mg in an inpatient randomized, cross-over study in non-treatment seeking non-dependent, opioid experienced individuals with current… Read more about this study

Who is it for?: Ages 21 to 58 yearsHealthy volunteers can take part
Conditions the study is for: Opioid Use Disorder
What is being tested?: NYX-783 and Oxycodone
Could I receive a placebo?: Yes, some participants may receive a placebo
How many people: 9 participants
Where: 2 sitesUnited States
Study dates: 15 May 2023to 30 Dec 2024
Phase: Phase 1
Are there results?: None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 21 to 58 years
All sexes
Healthy volunteers accepted
Adult

Who may be able to join

Voluntary, written, informed consent.
full scale and verbal IQs > 80 (Shipley Institute of Living IQ Screening Test).
Non-treatment seeking, non-dependent, opioid-experienced participants with low, opioid use via smoking or oral pills routes and with no need for medical detoxification from opiates and without past 12-month history of overdoses or medical detoxification for opioid withdrawal.
Participants must agree to use dual contraceptive methods during the study and refrain from donating sperm or ova during study or for 28 days after final dose of drug for ova and for 90 days after final dose of drug for sperm. Dual contraceptive methods include the use of a barrier contraceptive (i.e., condoms) in addition to another effective method that can prevent pregnancy (i.e., oral or parenteral contraceptives, intrauterine devices, spermicide, etc.).
Ability to understand and comply with study requirements and restrictions and provide a secondary contact if they cannot be reached.

Who cannot join

Meet current DSM-5 criteria of moderate to severe Substance Use Disorder (SUD) on either sedative, hypnotics, cocaine, methamphetamine, opiates or alcohol.
Daily heroin, fentanyl use requiring opiate detoxification and treatment.
Regular daily prescribed use of anticonvulsants, sedatives/hypnotics, other antihypertensives, anti-arrhythmics, antiretroviral medications, naltrexone, antabuse, grapefruit juice and St. John's wort products, glucocorticoids, stimulants (amphetamine like compounds), CNS active medications (other than stabilized use of antidepressants and anti-anxiety medications), metformin, or other medications such as benzodiazepines and sedating antidepressants that in the opinion of the investigators interfere with the study.
Women who are pregnant or nursing (as assessed by pregnancy tests during initial intake and upon CNRU admissions).
HIV seropositivity, hepatitis or other acute ongoing infectious disease considered clinically significant by the investigator.
Traumatic brain injury with loss of consciousness.

Show all 26Show fewer

Individuals with current or past history of seizure disorders.
Current or recent diagnosis within past 6-months of Major Depressive Disorder (MDD), bipolar disorder, schizophrenia, and schizoaffective disorder.
History of a neurodegenerative or neuro-inflammatory disorder including Huntington's, Parkinson's, Alzheimer's disease, or multiple sclerosis.
Known familial history or known presence of long QT syndrome, or a known history of past or current clinically significant arrhythmias or ischemic heart disease.
History of gastrointestinal disease or surgery (except simply appendectomy or hernia repair), leading to impaired drug absorption.
Uncorrected hypothyroidism or hyperthyroidism. Participants with compensated hypothyroidism with normal thyroid-stimulating hormone levels may be enrolled.
Sensitivity, allergy, or intolerance to N-methyl-D-aspartate receptor (NMDAR) ligands including ketamine, dextromethorphan, memantine, methadone, dextropropoxyphene, or ketobemidone and magnesium. Use of NMDAR-binding drugs within 60 days prior to dosing or during the study.
Received an investigational product or device within 30 days of dosing (or 5 half-lives whichever is longer).
Previously received NYX-783.
Screening QT interval corrected for heart rate (HR) by Fridericia's formula (QTcF) > 450 (males) or 470 (females) milliseconds (msec) or an ECG that is not suitable for QT measurements (e.g., poorly defined termination of T-wave in the investigator's opinion.
Heart rate ≤45 or >90 bpm at screening
Creatinine clearance <60ml/min at screening or history of renal disease as assessed by Investigator.
Uncontrolled Type I or Type II diabetes or uncontrolled hypertension characterized by fasting blood glucose > 126 mg/dl or postprandial blood glucose > 200 mg/dl, resting systolic blood pressure >160 mm Hg or resting diastolic >100 mm Hg, or clinically significant hypotension in the judgement of the Investigator as characterized by resting systolic blood pressure <90 mm Hg or resting diastolic blood pressure <60 mm Hg.
Impaired hepatic function characterized by a previous known diagnosis of chronic liver disease and/or the presence of:
direct bilirubin > 1.5x the upper limit of normal at screening
alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase, or gamma-glutamyl transferase (GGT) > 2x the upper limit of normal at screening.
History of severe COVID-19 infection requiring hospitalization, treatment with oxygen or mechanical ventilation, that may interfere with study participation as assessment by the Investigator.
Any participant with a medical history of Covid-19 infection (positive test) within the last 2 months, or current symptoms consistent with Covid-19 infection, as assessed by the Investigator.
Donated blood during the past 8 weeks.
Participants who do not report an increase in subjective opioid effect, as measured by the Drug Effects Questionnaire (DEQ, see below) by minimum of 10% or more to initial challenge with oxycodone in Session 1 will be excluded from the DDI phase sessions 2-7.

Trial locations and contacts

2 sites in 1 country.

United States2 sites

Cmhc/Cnru
New Haven, Connecticut, 06519
The Yale Stress Center: Yale University
New Haven, Connecticut, 06519

Other trials in United States

About this study

Official title: Clinical Evaluation of NMDA Modulator NYX-783 for OUD: Randomized, Double-blind, Placebo-Controlled Study to Assess Safety, Tolerability, and Pharmacokinetics of NYX-783 in Combination With Oxycodone (Study 1)

Read the detailed description

Outcomes will be cardiovascular (ECG monitoring, heart rate, blood pressure), respiratory, Clinical Opioid Withdrawal Scale (COWS), treatment emergent adverse events (TEAEs), and PK of NYX-783 levels in combination with Oxycodone. Secondary outcomes will be drug effects, subjective opiate withdrawal scale (SOWS), Drug Effects Questionnaire (DEQ), pupillary diameter, the Opioid Symptom Checklist (OSC), craving, stress and pain, and study drug levels during NYX-783 and Oxycodone combination challenge sessions.

Conditions: Opioid Use Disorder
Being tested: NYX-783, Placebo, Oxycodone
Medical subject headings: Opioid-Related Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

NYX-783Drug
Also called ((2S, 3R)-3-hydroxy-2-((S)-5-isobutyryl-1-oxo-2,5-diazaspiro[3.4]octan-2-yl)butanamide)
This study proposes to examine the safety, tolerability, and pharmacokinetics (PK) of NYX-783 at 50 mg and 150 mg doses versus Placebo (PBO) in combination with acute Oxycodone 15 mg and 30 mg in an inpatient randomized, cross-over study over 6 experimental sessions.
PlaceboDrug
This study proposes to examine the safety, tolerability, and pharmacokinetics (PK) of NYX-783 at 50 mg and 150 mg doses versus Placebo (PBO) in combination with acute Oxycodone 15 mg and 30 mg in an inpatient randomized, cross-over study over 6 experimental sessions.
OxycodoneDrug
This study proposes to examine the safety, tolerability, and pharmacokinetics (PK) of NYX-783 at 50 mg and 150 mg doses versus Placebo (PBO) in combination with acute Oxycodone 15 mg and 30 mg in an inpatient randomized, cross-over study over 6 experimental sessions.

Study groups in NCT05447286
Study group	Role	What they receive
Placebo + Oxycodone	Placebo comparator	Participants will receive placebo with + 15 mg oxycodone then placebo + 30 mg oxycodone in separate inpatient randomized sessions in this, cross-over study over 6 experimental sessions. Receives: Drug: Placebo; Drug: Oxycodone
NYX-783: 50 mg dose + Oxycodone	Active comparator	Participants will receive NYX-783 50 mg dose with + 15 mg oxycodone then NYX-783 50 mg + 30 mg oxycodone in separate inpatient randomized sessions in this, cross-over study over 6 experimental sessions. Receives: Drug: NYX-783; Drug: Oxycodone
NYX-783: 150 mg dose + Oxycodone	Active comparator	Participants will receive NYX-783 150 mg dose with + 15 mg oxycodone then NYX-783 150 mg + 30 mg oxycodone in separate inpatient randomized sessions in this, cross-over study over 6 experimental sessions. Receives: Drug: NYX-783; Drug: Oxycodone

What is being measured

The primary outcome is the main question the study is designed to answer.

Change in respiratory rate
Change in respiratory rate pre and post drug administration measured by counting breaths
Measured: over 6 sessions from baseline up to 3 weeks
Change in oxygenation saturation
Change in oxygenation saturation pre and post drug administration measured by pulse-oximeter
Measured: over 6 sessions from baseline up to 3 weeks
Change in blood pressure
Change in blood pressure pre and post drug administration measured by blood pressure monitor
Measured: over 6 sessions from baseline up to 3 weeks
Change in heart rate
Change in heart rate pre and post drug administration measured by blood pressure monitor
Measured: over 6 sessions from baseline up to 3 weeks
Change in body temperature
Change in body temperature pre and post drug administration measured by temperature monitor
Measured: over 6 sessions from baseline up to 3 weeks
Change in cardiac rate
Change in cardiac rate pre and post drug administration measured by EKG cardiac monitor
Measured: over 6 sessions from baseline up to 3 weeks
Change in cardiac rhythm
Change in cardiac rhythm pre and post drug administration measured by EKG cardiac monitor
Measured: over 6 sessions from baseline up to 3 weeks

Secondary outcomes (7)

treatment emergent adverse events (TEAES) from Systematic Assessment for Treatment Emergent Effects (SAFTEE)
The SAFTEE is a technique for the systematic assessment of side effects in clinical trials that rates the current severity of a wide range of somatic, behavioral and affective symptoms and tabulates occurrence of each TEAE symptom
Measured: over 6 sessions from baseline up to 3 weeks
Change in Clinical Opiate Withdrawal Scale (COWS)
COWS is an 11-item scale to rate common signs and symptoms of opiate withdrawal and monitor these symptoms over time. The summed score determines the stage/severity of opiate withdrawal and assess the level of physical dependence on opioids. Score: 5- 12 = mild; 13-24 = moderate; 25-36 = moderately severe; more than 36 = severe withdrawal
Measured: over 6 sessions from baseline up to 3 weeks
Change in Subjective Opioid Withdrawal Scale (SOWS)
SOWS is a self-administered scale for opioid withdrawal symptoms. It has16 symptoms whose intensity is rated on a scale of 0 (not at all) to 4 (extremely). Mild Withdrawal = score of 1-10, Moderate withdrawal = 11-20, Severe withdrawal = 21-30
Measured: over 6 sessions from baseline up to 3 weeks
Change in Drug Effects Questionnaire (DEQ)
The DEQ measures Good Drug Effect and consists of 11 questions with total score range from 0-100. Higher scores indicate more positive effects.
Measured: over 6 sessions from baseline up to 3 weeks
Change in Visual Analog Scale (VAS)
The VAS scales are 5 item drug effect self report ratings The visual analog questions were "Do you feel any Drug Effect?" "Do you like the drug?" "How high are you?" "Does the drug have any Good Effects?" "Does the drug have any Bad Effects?" and "How much do you DESIRE opiates?" The subjects responded by positioning an arrow along a 100-point line labeled with "not at all" at one end and "extremely" at the other. High scores show drug effect and craving, low scores show low drug effect and low craving
Measured: over 6 sessions from baseline up to 3 weeks
Change in Opioid Symptom Checklist (OSC)
The OSC is a 13-item opioid symptom checklist consisting of true/false questions designed to measure opioid effects (e.g., "My skin is itchy"). True scores total up to acute opiate positive and negative symptoms and low true scores will mean not feeling any of the negative and positive symptoms.
Measured: over 6 sessions from baseline up to 3 weeks
Change in pupillary diameter
pupil diameter size using pupilometer
Measured: over 6 sessions from baseline up to 3 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

15 May 202330 Dec 2024

First posted7 Jul 2022
Study start15 May 2023
Primary completion30 Dec 2024
Study completion30 Dec 2024

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for Opioid Use DisorderStudies of the same condition, open and under way.
More trials run by Yale UniversityThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 1
Primary purpose: Other
Allocation: Randomised
Intervention model: Crossover
Masking: Quadruple blind
Who is masked: Participant, Care provider, Investigator, Outcomes assessor
Enrolment: 9 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT05447286
Sponsor's protocol ID: 2000033008
Other IDs: UG3DA050322, NYX-783-1009
Status last verified: Mar 2025
First submitted: 21 Jun 2022
Last updated: 25 Mar 2025
Results posted: No
Data monitoring committee: Yes
FDA-regulated drug: Yes
FDA-regulated device: No
Individual data sharing: No

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Not yet recruiting
Prescribe to Prevent HIV: A Hybrid Trial Helping Addiction Clinics Prevent HIV & Infections Through Safer Drug Use Support
People Who Use Opioids/People With Opioid Use Disorder (OUD)
Enrolling by invitationObservational study
Development of an Interview-Informed Timeline Follow-Back (TLFB) for Opioid Use in the Era of Fentanyl
Substance Use Disorders (SUDs)
Not yet recruiting
Comprehensive Opioid Management and Breathing During Sleep
Sleep-Disordered Breathing, Chronic Opioid Use
Active, not recruitingPhase 2
Wellcome Leap Psilocybin for OUD
Opioid Use Disorder
Recruiting
Opioid and Pain Treatment in Indigenous Communities (OPTIC) Trial
Opioid Use Disorder, Opioid Misuse

All Opioid Use Disorder trials

Study at a glance

From the registry record, last updated by the sponsor on 25 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Clinical Evaluation of NMDA Modulator NYX-783 for OUD: Randomized, Double-blind, Placebo-Controlled Study to Assess Safety, Tolerability, and Pharmacokinetics of NYX-783 in Combination With Oxycodone (Study 1)
ClinicalTrials.gov ID: NCT05447286
Acronym / sponsor ID: 2000033008
Conditions: Opioid Use Disorder
Phase: Phase 1
Study type: Interventional
Recruitment status: Completed
Enrolment: 9 participants (actual)
Lead sponsor: Yale UniversityUniversity, hospital or other
Study start: 15 May 2023 (actual)
Primary completion: 30 Dec 2024 (actual)
Study completion: 30 Dec 2024 (actual)
First posted: 7 Jul 2022 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

Study design

Primary purpose: Other
Allocation: Randomised
Intervention model: Crossover
Masking: Quadruple blind (participant, care provider, investigator, outcomes assessor)
Number of arms: 3

Arm	Type	Receives
Placebo + Oxycodone	Placebo comparator	Drug: Placebo, Drug: OxycodoneParticipants will receive placebo with + 15 mg oxycodone then placebo + 30 mg oxycodone in separate inpatient randomized sessions in this, cross-over study over 6 experimental sessions.
NYX-783: 50 mg dose + Oxycodone	Active comparator	Drug: NYX-783, Drug: OxycodoneParticipants will receive NYX-783 50 mg dose with + 15 mg oxycodone then NYX-783 50 mg + 30 mg oxycodone in separate inpatient randomized sessions in this, cross-over study over 6 experimental sessions.
NYX-783: 150 mg dose + Oxycodone	Active comparator	Drug: NYX-783, Drug: OxycodoneParticipants will receive NYX-783 150 mg dose with + 15 mg oxycodone then NYX-783 150 mg + 30 mg oxycodone in separate inpatient randomized sessions in this, cross-over study over 6 experimental sessions.

Who may qualify

Ages: 21 to 58 years
Sex: All
Healthy volunteers: Accepted
Age groups: Adult

Key inclusion criteria (5 listed)

Voluntary, written, informed consent.
full scale and verbal IQs > 80 (Shipley Institute of Living IQ Screening Test).
Non-treatment seeking, non-dependent, opioid-experienced participants with low, opioid use via smoking or oral pills routes and with no need for medical detoxification from opiates and without past 12-month history of overdoses or medical detoxification for opioid withdrawal.
Participants must agree to use dual contraceptive methods during the study and refrain from donating sperm or ova during study or for 28 days after final dose of drug for ova and for 90 days after final dose of drug for sperm. Dual contraceptive methods include the use of a barrier contraceptive (i.e., condoms) in addition to another effective method that can prevent pregnancy (i.e., oral or parenteral contraceptives, intrauterine devices, spermicide, etc.).
Ability to understand and comply with study requirements and restrictions and provide a secondary contact if they cannot be reached.

Key exclusion criteria (26 listed)

Meet current DSM-5 criteria of moderate to severe Substance Use Disorder (SUD) on either sedative, hypnotics, cocaine, methamphetamine, opiates or alcohol.
Daily heroin, fentanyl use requiring opiate detoxification and treatment.
Regular daily prescribed use of anticonvulsants, sedatives/hypnotics, other antihypertensives, anti-arrhythmics, antiretroviral medications, naltrexone, antabuse, grapefruit juice and St. John's wort products, glucocorticoids, stimulants (amphetamine like compounds), CNS active medications (other than stabilized use of antidepressants and anti-anxiety medications), metformin, or other medications such as benzodiazepines and sedating antidepressants that in the opinion of the investigators interfere with the study.
Women who are pregnant or nursing (as assessed by pregnancy tests during initial intake and upon CNRU admissions).
HIV seropositivity, hepatitis or other acute ongoing infectious disease considered clinically significant by the investigator.

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
NYX-783Also: ((2S, 3R)-3-hydroxy-2-((S)-5-isobutyryl-1-oxo-2,5-diazaspiro[3.4]octan-2-yl)butanamide)This study proposes to examine the safety, tolerability, and pharmacokinetics (PK) of NYX-783 at 50 mg and 150 mg doses versus Placebo (PBO) in combination with acute Oxycodone 15 mg and 30 mg in an inpatient randomized, cross-over study over 6 experimental sessions.	Drug	NYX-783: 150 mg dose + Oxycodone, NYX-783: 50 mg dose + Oxycodone
PlaceboThis study proposes to examine the safety, tolerability, and pharmacokinetics (PK) of NYX-783 at 50 mg and 150 mg doses versus Placebo (PBO) in combination with acute Oxycodone 15 mg and 30 mg in an inpatient randomized, cross-over study over 6 experimental sessions.	Drug	Placebo + Oxycodone
OxycodoneThis study proposes to examine the safety, tolerability, and pharmacokinetics (PK) of NYX-783 at 50 mg and 150 mg doses versus Placebo (PBO) in combination with acute Oxycodone 15 mg and 30 mg in an inpatient randomized, cross-over study over 6 experimental sessions.	Drug	NYX-783: 150 mg dose + Oxycodone, NYX-783: 50 mg dose + Oxycodone, Placebo + Oxycodone

Primary outcome

Change in respiratory rate
Time frame: over 6 sessions from baseline up to 3 weeks
Change in respiratory rate pre and post drug administration measured by counting breaths
Change in oxygenation saturation
Time frame: over 6 sessions from baseline up to 3 weeks
Change in oxygenation saturation pre and post drug administration measured by pulse-oximeter
Change in blood pressure
Time frame: over 6 sessions from baseline up to 3 weeks
Change in blood pressure pre and post drug administration measured by blood pressure monitor
Change in heart rate
Time frame: over 6 sessions from baseline up to 3 weeks
Change in heart rate pre and post drug administration measured by blood pressure monitor
Change in body temperature
Time frame: over 6 sessions from baseline up to 3 weeks
Change in body temperature pre and post drug administration measured by temperature monitor
Change in cardiac rate
Time frame: over 6 sessions from baseline up to 3 weeks
Change in cardiac rate pre and post drug administration measured by EKG cardiac monitor
Change in cardiac rhythm
Time frame: over 6 sessions from baseline up to 3 weeks
Change in cardiac rhythm pre and post drug administration measured by EKG cardiac monitor

7 secondary outcomes

treatment emergent adverse events (TEAES) from Systematic Assessment for Treatment Emergent Effects (SAFTEE)
Time frame: over 6 sessions from baseline up to 3 weeks
Change in Clinical Opiate Withdrawal Scale (COWS)
Time frame: over 6 sessions from baseline up to 3 weeks
Change in Subjective Opioid Withdrawal Scale (SOWS)
Time frame: over 6 sessions from baseline up to 3 weeks
Change in Drug Effects Questionnaire (DEQ)
Time frame: over 6 sessions from baseline up to 3 weeks
Change in Visual Analog Scale (VAS)
Time frame: over 6 sessions from baseline up to 3 weeks
Change in Opioid Symptom Checklist (OSC)
Time frame: over 6 sessions from baseline up to 3 weeks
Change in pupillary diameter
Time frame: over 6 sessions from baseline up to 3 weeks

Results and safety

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 25 Mar 2025.
Individual participant dataSharing planned: No

Related trials for Opioid Use Disorder

Not yet recruiting
Prescribe to Prevent HIV: A Hybrid Trial Helping Addiction Clinics Prevent HIV & Infections Through Safer Drug Use Support
People Who Use Opioids/People With Opioid Use Disorder (OUD)
Enrolling by invitationObservational study
Development of an Interview-Informed Timeline Follow-Back (TLFB) for Opioid Use in the Era of Fentanyl
Substance Use Disorders (SUDs)
Not yet recruiting
Comprehensive Opioid Management and Breathing During Sleep
Sleep-Disordered Breathing, Chronic Opioid Use
Active, not recruitingPhase 2
Wellcome Leap Psilocybin for OUD
Opioid Use Disorder
Recruiting
Opioid and Pain Treatment in Indigenous Communities (OPTIC) Trial
Opioid Use Disorder, Opioid Misuse

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Rajita Sinha, PhD principal investigator

Yale University

2 sites in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing NYX-783 and Oxycodone in people with Opioid Use Disorder, run by Yale University at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 26 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 25 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in respiratory rate (time frame: over 6 sessions from baseline up to 3 weeks). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05447286.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Mar 2025.